23:28 , Jul 14, 2014 |  BC Extra  |  Politics & Policy

India caps prices of 50 CV and diabetes drugs

India's National Pharmaceutical Pricing Authority ( NPPA ) Januvia sitagliptin from Merck & Co. Inc. (NYSE:MRK) and Volibo voglibose from Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA). The only non-insulin diabetes drugs included on India's list...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Clinical News

Linagliptin: Phase III data

A meta-analysis of 8 double-blind Phase III trials in patients with Type II diabetes showed that once-daily linagliptin (n=3,319) led to a significantly lower incidence of cardiovascular death, non-fatal stroke, non-fatal MI and hospitalization for...
08:00 , Mar 11, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes a-Glucosidase A study in rats identified triazole-based inhibitors of a-glucosidase that could help treat type 2 diabetes. In rats, 50 mg/kg of two...
07:00 , Jun 2, 2008 |  BC Week In Review  |  Clinical News

Basen voglibose: Phase III data

In a double-blind, Japanese Phase III trial in 1,778 patients, Basen met the primary endpoint of a significant 41% decrease vs. placebo in cases of new onset Type II diabetes (p=0.0014). Basen also met the...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Clinical News

Basen voglibose regulatory update

Takeda submitted a Japanese marketing application to expand the label for Basen voglibose tablets 0.2 mg and Basen OD tablets 0.2 mg to prevent onset of Type II diabetes in patients with impaired glucose tolerance....
08:00 , Dec 14, 1998 |  BioCentury  |  Tools & Techniques

Diabetes Pipeline

Diabetes Pipeline...